1.The Korean Academy of Asthma Allergy and Clinical Immunology guidelines for sublingual immunotherapy
Gwanghui RYU ; Hye Mi JEE ; Hwa Young LEE ; Sung-Yoon KANG ; Kyunghoon KIM ; Ju Hee KIM ; Kyung Hee PARK ; So-Young PARK ; Myong Soon SUNG ; Youngsoo LEE ; Eun-Ae YANG ; Jin-Young MIN ; Eun Kyo HA ; Sang Min LEE ; Yong Won LEE ; Eun Hee CHUNG ; Sun Hee CHOI ; Young-Il KOH ; Seon Tae KIM ; Dong-Ho NAHM ; Jung Won PARK ; Jung Yeon SHIM ; Young Min AN ; Man Yong HAN ; Jeong-Hee CHOI ; Yoo Seob SHIN ; Doo Hee HAN ;
Allergy, Asthma & Respiratory Disease 2024;12(3):125-133
		                        		
		                        			
		                        			 Allergen immunotherapy (AIT) has been used for over a century and has been demonstrated to be effective in treating patients with various allergic diseases. AIT allergens can be administered through various routes, including subcutaneous, sublingual, intralymphatic, oral, or epicutaneous routes. Sublingual immunotherapy (SLIT) has recently gained clinical interest, and it is considered an alternative treatment for allergic rhinitis (AR) and asthma. This review provides an overview of the current evidence-based studies that address the use of SLIT for treating AR, including (1) mechanisms of action, (2) appropriate patient selection for SLIT, (3) the current available SLIT products in Korea, and (4) updated information on its efficacy and safety. Finally, this guideline aims to provide the clinician with practical considerations for SLIT. 
		                        		
		                        		
		                        		
		                        	
2.Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment
Hyo Seon RYU ; Hyun Jung KIM ; Woong Bae JI ; Byung Chang KIM ; Ji Hun KIM ; Sung Kyung MOON ; Sung Il KANG ; Han Deok KWAK ; Eun Sun KIM ; Chang Hyun KIM ; Tae Hyung KIM ; Gyoung Tae NOH ; Byung-Soo PARK ; Hyeung-Min PARK ; Jeong Mo BAE ; Jung Hoon BAE ; Ni Eun SEO ; Chang Hoon SONG ; Mi Sun AHN ; Jae Seon EO ; Young Chul YOON ; Joon-Kee YOON ; Kyung Ha LEE ; Kyung Hee LEE ; Kil-Yong LEE ; Myung Su LEE ; Sung Hak LEE ; Jong Min LEE ; Ji Eun LEE ; Han Hee LEE ; Myong Hoon IHN ; Je-Ho JANG ; Sun Kyung JEON ; Kum Ju CHAE ; Jin-Ho CHOI ; Dae Hee PYO ; Gi Won HA ; Kyung Su HAN ; Young Ki HONG ; Chang Won HONG ; Jung-Myun KWAK ;
Annals of Coloproctology 2024;40(2):89-113
		                        		
		                        			
		                        			 Colorectal cancer is the third most common cancer in Korea and the third leading cause of death from cancer. Treatment outcomes for colon cancer are steadily improving due to national health screening programs with advances in diagnostic methods, surgical techniques, and therapeutic agents.. The Korea Colon Cancer Multidisciplinary (KCCM) Committee intends to provide professionals who treat colon cancer with the most up-to-date, evidence-based practice guidelines to improve outcomes and help them make decisions that reflect their patients’ values and preferences. These guidelines have been established by consensus reached by the KCCM Guideline Committee based on a systematic literature review and evidence synthesis and by considering the national health insurance system in real clinical practice settings. Each recommendation is presented with a recommendation strength and level of evidence based on the consensus of the committee. 
		                        		
		                        		
		                        		
		                        	
5.Chest Pain in a Renal Transplant Recipient due to Concomitant Cytomegalovirus and Herpes Simplex Virus Esophagitis
Seok Hyung KANG ; Myong Ki BAEG ; Sun Hye KO ; Hyunjung HWANG ; Sang Yeop YI ; Sung Jin MOON ; Jeongkeun PARK
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2019;19(1):61-64
		                        		
		                        			
		                        			Chest pain in kidney transplant patients is usually caused by cardiac or pulmonary problems. However, it may be rarely caused by opportunistic esophageal infections. A 66-year-old female kidney transplant recipient was admitted because of chest pain. She had been treated with high-dose steroid and immunosuppressants for acute T-cell-mediated rejection. Cardiologic and pulmonary evaluations had normal results. Endoscopic examination revealed three clear ulcerative lesions in the esophagus. Histological and immunohistochemical staining of the endoscopic biopsy specimens revealed coinfection of herpes simplex virus and cytomegalovirus. The patient was treated with intravenous ganciclovir for 2 weeks. Her symptoms completely resolved, and follow-up endoscopy revealed complete healing of the previous ulcers. Viral esophagitis should be considered in the differential diagnosis in kidney transplant recipients presenting with chest pain.
		                        		
		                        		
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Biopsy
		                        			;
		                        		
		                        			Chest Pain
		                        			;
		                        		
		                        			Coinfection
		                        			;
		                        		
		                        			Cytomegalovirus
		                        			;
		                        		
		                        			Diagnosis, Differential
		                        			;
		                        		
		                        			Endoscopy
		                        			;
		                        		
		                        			Esophagitis
		                        			;
		                        		
		                        			Esophagus
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Ganciclovir
		                        			;
		                        		
		                        			Herpes Simplex
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunosuppressive Agents
		                        			;
		                        		
		                        			Kidney
		                        			;
		                        		
		                        			Kidney Transplantation
		                        			;
		                        		
		                        			Simplexvirus
		                        			;
		                        		
		                        			Thorax
		                        			;
		                        		
		                        			Transplant Recipients
		                        			;
		                        		
		                        			Ulcer
		                        			
		                        		
		                        	
6.Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
Eun Gyeong LEE ; Hyok Jo KANG ; Myong Cheol LIM ; Boyoung PARK ; Soo Jin PARK ; So Youn JUNG ; Seeyoun LEE ; Han Sung KANG ; Sang Yoon PARK ; Boram PARK ; Jungnam JOO ; Jai Hong HAN ; Sun Young KONG ; Eun Sook LEE
Cancer Research and Treatment 2019;51(1):280-288
		                        		
		                        			
		                        			PURPOSE: The purpose of this study was to investigate decision patterns to reduce the risks of BRCArelated breast and gynecologic cancers in carriers of BRCA pathogenic variants. We found a change in risk-reducing (RR) management patterns after December 2012, when the National Health Insurance System (NHIS) of Korea began to pay for BRCA testing and riskreducing salpingo-oophorectomy (RRSO) in pathogenic-variant carriers. MATERIALS AND METHODS: The study group consisted of 992 patients, including 705 with breast cancer (BC), 23 with ovarian cancer (OC), 10 with both, and 254 relatives of high-risk patients who underwent BRCA testing at the National Cancer Center of Korea from January 2008 to December 2016.We analyzed patterns of and factors in RR management. RESULTS: Of the 992 patients, 220 (22.2%) were carriers of BRCA pathogenic variants. About 92.3% (203/220) had a family history of BC and/or OC,which significantly differed between BRCA1 and BRCA2 carriers (p < 0.001). All 41 male carriers chose surveillance. Of the 179 female carriers, 59 of the 83 carriers (71.1%) with BC and the 39 of 79 unaffected carriers (49.4%) underwent RR management. None of the carriers affected with OC underwent RR management. Of the management types, RRSO had the highest rate (42.5%) of patient choice. The rate of RR surgery was significantly higher after 2013 than before 2013 (46.3% [74/160] vs. 31.6% [6/19], p < 0.001). CONCLUSION: RRSO was the preferred management for carriers of BRCA pathogenic variants. The most important factors in treatment choice were NHIS reimbursement and/or the severity of illness.
		                        		
		                        		
		                        		
		                        			Breast
		                        			;
		                        		
		                        			Breast Neoplasms
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Korea
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			National Health Programs
		                        			;
		                        		
		                        			Ovarian Neoplasms
		                        			;
		                        		
		                        			Prophylactic Surgical Procedures
		                        			
		                        		
		                        	
7.Revision Superficial Temporal Artery-Middle Cerebral Artery Bypass Surgery for Recurrent Acute Ischemic Stroke Due to Delayed Occlusion of the Bypass Graft.
Yun Hee CHOI ; Hyun Seok PARK ; Myong Jin KANG ; Jae Kwan CHA
Journal of Cerebrovascular and Endovascular Neurosurgery 2018;20(2):127-132
		                        		
		                        			
		                        			Intravenous thrombolysis (IVT) and endovascular treatment (EVT) are currently the main treatments for reperfusion in acute ischemic stroke. Although the EVT recanalization rate has increased, unsuccessful recanalization is still observed in 10-30% cases. Superficial temporal artery-middle cerebral artery (STA-MCA) bypass is considered a rescue therapy in such cases, but in most centers it is not usually performed for acute ischemic stroke. Graft occlusion is rare following STA-MCA bypass, but it might lead to recurrent ischemic stroke. We hereby report on a patient with right MCA infarction and in whom EVT failed due to complete proximal internal carotid artery occlusion. He underwent an emergency STA-MCA bypass, resulting in a full recovery of his motor weakness. However, six months later, the patient experienced recurrent acute ischemic stroke due to bypass graft occlusion. His EVT failed again but revision bypass surgery, using STA remnant branch, was successful with full motor weakness recovery. We recommend a revision bypass surgery as a feasible therapeutic option for recurrent cerebral infarction caused by delayed STA graft occlusion.
		                        		
		                        		
		                        		
		                        			Carotid Artery, Internal
		                        			;
		                        		
		                        			Cerebral Arteries*
		                        			;
		                        		
		                        			Cerebral Infarction
		                        			;
		                        		
		                        			Cerebral Revascularization
		                        			;
		                        		
		                        			Emergencies
		                        			;
		                        		
		                        			Graft Occlusion, Vascular
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Infarction, Middle Cerebral Artery
		                        			;
		                        		
		                        			Reoperation
		                        			;
		                        		
		                        			Reperfusion
		                        			;
		                        		
		                        			Stroke*
		                        			;
		                        		
		                        			Transplants*
		                        			
		                        		
		                        	
8.Asymptomatic Splenic Cysts in an Immunocompromised Patient: Should They Be Investigated.
Hyunjung HWANG ; Myong Ki BAEG ; Pumsoo KIM ; Yu Jin KIM ; Seok Hyung KANG
The Korean Journal of Gastroenterology 2018;72(4):209-212
		                        		
		                        			
		                        			Splenic abscess is a rare disease that generally occurs in immunocompromised patients. It is difficult to distinguish between splenic abscesses and cysts using imaging studies, especially if they are asymptomatic. A 50-year-old asymptomatic man who had received steroid therapy for underlying rheumatoid arthritis was referred to a university hospital due to presence of several splenic cysts, with the largest being 3.5 cm in diameter. Percutaneous aspiration was performed, and fluid analysis showed cysts infected by extended-spectrum, beta-lactamase-producing Escherichia coli. The patient was treated with ertapenem for four weeks, and the lesion disappeared on follow-up imaging studies. Splenic abscess should be included as a differential diagnosis of splenic cystic lesions in immunocompromised patients.
		                        		
		                        		
		                        		
		                        			Abscess
		                        			;
		                        		
		                        			Arthritis, Rheumatoid
		                        			;
		                        		
		                        			Diagnosis, Differential
		                        			;
		                        		
		                        			Escherichia coli
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunocompromised Host*
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Rare Diseases
		                        			
		                        		
		                        	
9.Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors.
Myong Hoon IHN ; Duck Woo KIM ; Sukki CHO ; Heung Kwon OH ; Sanghoon JHEON ; Kwhanmien KIM ; Eun SHIN ; Hye Seung LEE ; Jin Haeng CHUNG ; Sung Bum KANG
Cancer Research and Treatment 2017;49(1):104-115
		                        		
		                        			
		                        			PURPOSE: Prognostic factors in patients with pulmonary metastases (PM) from colorectal cancer (CRC) are still controversial. This study assessed oncologic outcomes and prognostic factors in patients with metachronous PM from CRC. MATERIALS AND METHODS: Between June 2003 and December 2011, 122 patients with CRC underwent curative resection of PM detected at least 4 months after CRC resection. Clinico-pathological factors selected from the prospectively maintained database were analyzed retrospectively. RESULTS: The median disease-free interval (DFI) between resection of the primary tumor and detection of PM was 22.0 months (range, 4 to 85 months). Solitary PM were detected in 77 patients (63.1%), with a median maximal tumor diameter of 12.0 mm (range, 2 to 70 mm). Of 52 patients who underwent mediastinal lymph node (LN) dissection, eight patients had LN involvement. Five-year overall survival and disease-free survival (DFS) rates after initial pulmonary metastasectomy were 66.4% and 50.9%, respectively. DFI, mediastinal LN involvement, and the number and distribution of PM were significantly prognostic factors for DFS. In multivariable analysis DFI ≥ 12 months, solitary lesion, and absence of mediastinal LN involvement were independently prognostic for DFS. Of the 122 patients, 48 patients (39.3%) developed recurrent PM a median 13.0 months after initial pulmonary metastasectomy. Recurrent DFI was independently prognostic of DFS in patients who underwent repeated pulmonary metastasectomy. CONCLUSION: There is a potential survival benefit for patients with metachronous PM from CRC who undergo pulmonary metastasectomy, even those with recurrent PM. Pulmonary metastasectomy should be considered in selected patients, particularly those with longer DFI, solitary lesions, and absence of mediastinal LN involvement.
		                        		
		                        		
		                        		
		                        			Colorectal Neoplasms*
		                        			;
		                        		
		                        			Disease-Free Survival
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lymph Nodes
		                        			;
		                        		
		                        			Metastasectomy
		                        			;
		                        		
		                        			Neoplasm Metastasis*
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Survival Rate*
		                        			
		                        		
		                        	
10.Development and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K).
Se Hyun NAM ; Hyun Jin CHOI ; Woo Dae KANG ; Seok Mo KIM ; Myong Cheol LIM ; Sang Yoon PARK ; Jung Sup KIM ; Byoung Gie KIM ; Duk Soo BAE ; Jeong won LEE ; Tae Joong KIM ; Taejong SONG
Journal of Korean Medical Science 2016;31(12):1969-1975
		                        		
		                        			
		                        			Given the growing number of cancer patients and the resulting increase in the administration of chemotherapeutic agents, convenient and effective methods for measuring the symptoms and quality of life associated with the hand-foot syndrome (HFS) are needed. Therefore, the aim of this study was to develop and validate the Korean version of the hand-foot skin reaction and quality of life questionnaire (HF-QoL-K), comprising a 20-item symptom domain and an 18-item daily activity domain. After we developed the HF-QoL-K, 209 Korean patients with gynecologic cancer who were undergoing chemotherapeutic agents relating the HFS were asked to fill in the questionnaire. The content validity, internal consistency reliability, and test-retest reliability were evaluated. The internal validity index, Cronbach’s alpha coefficient, and intra-class correlation coefficient of the HF-QoL-K were 0.90, 0.958, and 0.825 (95% confidence interval [CI], 0.774–0.865), respectively. The scatter plot (Pearson correlation coefficient, 0.826) and the Bland-Altman plot for test-retest reliability were also acceptable. The HF-QoL-K instrument is a valid and reliable questionnaire for the measurement of the symptoms and quality of life in Korean cancer patients suffering HFS.
		                        		
		                        		
		                        		
		                        			Drug Therapy
		                        			;
		                        		
		                        			Hand-Foot Syndrome
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Quality of Life*
		                        			;
		                        		
		                        			Reproducibility of Results
		                        			;
		                        		
		                        			Skin*
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail